Batavia Biosciences, a technology services provider, has partnered with an international consortium coordinated by PATH, a non-profit organization focused on global health, to develop and manufacture oral poliovirus vaccines (nOPV). The project is funded by the Bill & Melinda Gates Foundation.

In support of the polio eradication initiative, the parties are developing nOPV candidates to reduce the risk from rare cases of vaccine-associated disease. The strains are intended to be stockpiled as protection against possible future outbreaks after polio has been eradicated.

The candidate vaccine strains currently in manufacturing at Batavia Biosciences have been developed by the National Institute for Biological Standards and Control in the United Kingdom, the US Centers for Disease Control and Prevention, the US Food and Drug Administration, and the University of California at San Francisco. Batavia Biosciences says it works with an OPV vaccine manufacturer, Bio Farma, in Indonesia, under the nOPV consortium managed by PATH.

Source: Batavia Biosciences